Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sprint Bioscience AB

http://www.sprintbioscience.com/

Latest From Sprint Bioscience AB

Korea Gains Speed In Race For NASH Therapies

NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.

South Korea Research & Development

Asia Deal Watch: Takeda Will Employ Engitix’s ECM Tech In Liver Fibrosis Indications

Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.

Deals Business Strategies

Asia Deal Watch: Takeda On A Deal Spree

Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery pact. AstraZeneca gains expanded rights to Kyowa Hakko Kirin’s Fasenra.

Asia Pacific Commercial

Bayer Reiterates Pharma Commitment Post-Monsanto, Plays Up Pipeline

German conglomerate says five recent launches led by Xarelto and Eylea are expected to bring in more than $11bn in peak sales, a 33% increase over previous projections. CEO Baumann pledges to make the investments needed to continue growing the pharma business.

Business Strategies M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register